Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3449418 | 0.98 | NOTUM (0.53) | NOTUMALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL14020825 | 0.82 | NOTUM (0.71) | NOTUMALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL2627241 | 0.78 | NOTUM (0.82) | NOTUMALDH1A1TSHRKMT2ALMNA | |
| SCHEMBL2048542 | 0.78 | ALDH1A1 (0.62) | NOTUMALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL4202843 | 0.77 | TP53 (0.61) | NOTUMALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL2356727 | 0.74 | CYP1A2 (0.44) | ALDH1A1KMT2AMAPTSMN1; SMN2HTT | |
| SCHEMBL30038775 | 0.74 | CYP1A2 (0.44) | ALDH1A1KMT2AMAPTSMN1; SMN2HTT | |
| SCHEMBL1570379 | 0.74 | ALDH1A1 (0.51) | NOTUMALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL221145 | 0.73 | ALDH1A1 (0.56) | NOTUMALDH1A1TSHRKMT2ALMNA | |
| SCHEMBL30880770 | 0.73 | CYP1B1 (0.53) | ALDH1A1LMNAPTGS2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | claimed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| EP-3714012-B1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| US-20210102093-A1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2021-04-08 | — | — | US | disclosed |
| US-10899945-B2 | Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates | BASF SE (DE) | 2021-01-26 | — | — | US | disclosed |
| EP-3714012-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200299547-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-24 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-3334794-B1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019101555-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2019-05-31 | — | — | WO | disclosed |
| US-8318755-B2 | Inhibitors of SYK and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2323993-A2 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | NOTUM 828/4885ALDH1A1 3700/4885TSHR 2274/4885 |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | NOTUM 828/4885ALDH1A1 3700/4885TSHR 2274/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | NOTUM 4113/4885ALDH1A1 1132/4885TSHR 231/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | NOTUM 828/4885ALDH1A1 3700/4885TSHR 2274/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NOTUM 3654/4885ALDH1A1 4184/4885TSHR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.